AR055377A1 - Formulacion de inhibidor del factor xa y metodo - Google Patents

Formulacion de inhibidor del factor xa y metodo

Info

Publication number
AR055377A1
AR055377A1 ARP060103576A ARP060103576A AR055377A1 AR 055377 A1 AR055377 A1 AR 055377A1 AR P060103576 A ARP060103576 A AR P060103576A AR P060103576 A ARP060103576 A AR P060103576A AR 055377 A1 AR055377 A1 AR 055377A1
Authority
AR
Argentina
Prior art keywords
factor
inhibitor
formulation
cyclodextrin
beta
Prior art date
Application number
ARP060103576A
Other languages
English (en)
Inventor
Munir N Nassar
Uday S Gogate
Timothy M Malloy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR055377A1 publication Critical patent/AR055377A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Una formulacion de inhibidor del Factor Xa inyectable la cual incluye el inhibidor del Factor Xa razaxaban o apixaban, un agente de solubilizacion el cual es una beta-ciclodextrina, sustituida, preferiblemente, sulfobutil éter-beta-ciclodextrina (SBE-CD) o hidroxipropil-Beta-ciclodextrina (HPB-CD), y agua. También un método para prevenir o tratar trombosis venosa, trombosis de vena profunda y síndrome coronario agudo que emplea la formulacion anterior.
ARP060103576A 2005-08-17 2006-08-16 Formulacion de inhibidor del factor xa y metodo AR055377A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70907705P 2005-08-17 2005-08-17
US11/464,519 US20070191306A1 (en) 2005-08-17 2006-08-15 FACTOR Xa INHIBITOR FORMULATION AND METHOD

Publications (1)

Publication Number Publication Date
AR055377A1 true AR055377A1 (es) 2007-08-22

Family

ID=37654897

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103576A AR055377A1 (es) 2005-08-17 2006-08-16 Formulacion de inhibidor del factor xa y metodo

Country Status (10)

Country Link
US (2) US20070191306A1 (es)
EP (1) EP1924291A2 (es)
JP (1) JP2009504746A (es)
AR (1) AR055377A1 (es)
BR (1) BRPI0614827A2 (es)
CA (1) CA2619214A1 (es)
MX (1) MX2008002057A (es)
PE (1) PE20070378A1 (es)
TW (1) TW200800270A (es)
WO (1) WO2007022165A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3106463T6 (da) 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
RU2012101214A (ru) * 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
EP3251660B1 (en) 2010-02-25 2019-10-16 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
SG11201408511QA (en) * 2012-06-27 2015-01-29 Takeda Pharmaceutical Liquid preparations of amines and organic acids stabilized by salts
SG10201702048VA (en) * 2012-09-26 2017-04-27 Bristol Myers Squibb Holdings Ireland Apixaban liquid formulations
CN104650072B (zh) * 2013-11-18 2016-03-16 成都苑东生物制药股份有限公司 一种吡啶类衍生物
PE20181888A1 (es) * 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN115715770B (zh) * 2021-08-24 2024-01-26 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
WO2023072967A1 (en) 2021-10-27 2023-05-04 Pharma-Data S.A. Apixaban suspension and preparation method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4745105A (en) * 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
JP2003509409A (ja) * 1999-09-13 2003-03-11 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド アザシクロアルカノンセリンプロテアーゼ阻害剤
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2726702A1 (en) * 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Also Published As

Publication number Publication date
JP2009504746A (ja) 2009-02-05
CA2619214A1 (en) 2007-02-22
BRPI0614827A2 (pt) 2011-04-19
PE20070378A1 (es) 2007-05-04
MX2008002057A (es) 2008-04-16
WO2007022165A2 (en) 2007-02-22
US20070191306A1 (en) 2007-08-16
TW200800270A (en) 2008-01-01
EP1924291A2 (en) 2008-05-28
US20090291913A1 (en) 2009-11-26
WO2007022165A3 (en) 2007-08-23
WO2007022165B1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
AR055377A1 (es) Formulacion de inhibidor del factor xa y metodo
AR116859A2 (es) Métodos para tratar la esclerosis múltiple progresiva
AR037755A1 (es) Composiciones acuosas con contenido de metronidazol
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
BR112012013883A2 (pt) método
NO20055304L (no) Metode for behandling av en olje- eller gassbronn og biologisk nedbrytbart fluidsystem med lav toksisitet
AR032643A1 (es) Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
ECSP088238A (es) Proceso y equipo para mejorar las propiedades de flujo del petróleo crudo
AR055351A1 (es) Metodos y composiciones para el control de finos de formacion y para la reduccion de reflujo de agente de sosten
CU23794B7 (es) Inhibidores macrocíclicos de la replicación del virus de la hepatitis c
CO4920246A1 (es) Composicion liofilizada que comprende epotilona a y b con manitol o ciclodextrina .
CY1109295T1 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
SV2009003227A (es) Composiciones de inhibidores de chk 1 ref. x-17672
PE20040895A1 (es) Formulacion de complejo de aripiprazol
RS52678B (en) PROCEDURE FOR TREATMENT OF IRITABLE TEST SYNDROME WITH PREDOMINANT CONSTIPATION
AR054243A1 (es) Metodos y composiciones para retardar la liberacion de quimicos de tratamiento
AR073204A1 (es) Tratamientos de bananas.
CL2009000844A1 (es) Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es agonista de pten.
CL2007002026A1 (es) Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
AR055464A1 (es) Ensamble de cartucho
AR086543A1 (es) Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
AR058667A1 (es) Mezclas de polimeros para fluidos entrecruzados
AR065564A1 (es) Composiciones farmaceuticas que comprenden un agente calciletico
UY39504A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión

Legal Events

Date Code Title Description
FA Abandonment or withdrawal